Latest NewsFDA NewsAdverse Event ManagementSupportive CareDisparities in Cancer CareDrug SafetyRadiation OncologySurvivorship Practice ManagementPreventionContributorsSponsored
Expert ConnectionsMorning RoundsThe VitalsPodcastsVideosBetween the LinesMeeting of the MindsTraining Academy
Conference CoverageConference Listing
Publications
Continuing Education
Case-Based Digest Rx Road MapWebinarsCancer Summary SlidesMPN Symptom ManagementEvents
SubscribePartners
Brain Cancer
Breast CancerBreast Cancer
Gastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal Cancer
Genitourinary CancerGenitourinary CancerGenitourinary CancerGenitourinary Cancer
Gynecologic CancersGynecologic CancersGynecologic CancersGynecologic Cancers
Head and Neck Cancers
HematologyHematologyHematologyHematologyHematologyHematology
Lung Cancer
Pediatric Cancer
Sarcomas
Skin CancerSkin Cancer
Advanced Practice Corner Logo
    Brain Cancer
    Breast CancerBreast Cancer
    Gastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal Cancer
    Genitourinary CancerGenitourinary CancerGenitourinary CancerGenitourinary Cancer
    Gynecologic CancersGynecologic CancersGynecologic CancersGynecologic Cancers
    Head and Neck Cancers
    HematologyHematologyHematologyHematologyHematologyHematology
    Lung Cancer
    Pediatric Cancer
    Sarcomas
    Skin CancerSkin Cancer
    Advanced Practice Corner Logo
        • Publications
        • Subscribe
        • Partners
      Advertisement

      ADT and Dementia Link Gains Evidence in Recent Update

      April 10, 2017
      By Allie Casey
      Article

      A recent review has found substantial evidence linking androgen deprivation therapy (ADT) to dementia in patients with prostate cancer.

      Kevin Nead, MD, MPhil

      Kevin Nead, MD, MPhil

      Kevin Nead, MD, MPhil

      Androgen deprivation therapy (ADT) is a common treatment for prostate cancer, which lowers testosterone. A recent analysis has found substantial evidence linking ADT to dementia.

      A previous study done by researchers at the Perelman School of Medicine at the University of Pennsylvania found that men who received ADT may be at an increased risk for dementia, including Alzheimer’s disease, compared with men who were not treated with the therapy. The absolute increased risk of developing dementia, they determined, was 4.4% at 5 years.1

      Since that study was published in October 2016, researchers have looked into it further. This analysis, published in Prostate Cancer and Prostatic Diseases,2 looked at data from 4 different, global databases (PubMed, Web of Science, Embase, PsycINFO), comparing studies on ADT patients and dementia and Alzheimer’s. All the existing studies together, researchers said, support the link to dementia, and show a possible link to Alzheimer’s.

      “This analysis tells us that the composite message of existing studies is that androgen deprivation therapy is associated with dementia,” according to Kevin Nead, MD, MPhil, a radiation oncology resident with the Perelman School of Medicine at the University of Pennsylvania and an author on both studies.

      From the 4 databases, there were 9 studies on the outcome of dementia among patients exposed to ADT versus a lesser-exposed comparison group (eg, ADT vs no ADT or continuous ADT vs intermittent). An analysis of 50,541 patients showed an increased risk of dementia among those who had undergone ADT. Nead clarified that this analysis shows correlation, although not causation at this point.

      “Research shows androgens play a key role in neuron maintenance and growth, so the longer you undergo this therapy to decrease androgens, the more it may impact the brain’s normal functions,” Nead said.

      A link between ADT and Alzheimer’s was found as well, but it was not as clearly defined as the link to dementia.

      When the earlier study was published, Nead stated, “It would be really hard to justify not using a medication that we know extends life for a possible negative consequence that at this point is potential, probably at best, but nor proven.”

      The more recent analysis suggests that the evidence between ADT and neurocognitive dysfunction continues to grow, said Nead, and should be a part of the conversations between doctors and patients: “There’s enough evidence of these links that patients should know about them when considering their options.”

      References

      • Nead KT, Gaskin G, Chester C, et al. Association between androgen deprivation therapy and risk of dementia. JAMA Oncol. 2017;3(1):49-55.
      • Nead KT, Sinha S, Nguyen PL. Androgen deprivation therapy for prostate cancer and dementia risk: a systematic review and meta-analysis [published online before print March 28, 2017]. Prostate Cancer Prostatic Dis.

      Newsletter

      Stay up to date on recent advances in oncology nursing and patient care.

      Subscribe Now!
      Recent Videos
      Man standing in front of Oncology Nursing News-branded backdrop
      Brenda Martone
      Arash Rezazadeh Kalebasty
      Leapman
      Laura Wood on the Integration of Avelumab, Erdafitinib, and Enfortumab Vedotin into Urothelial Cancer Care
      Related Content

      Blue image of kidneys with renal tubules highlighted in red

      Nivolumab Plus Cabozantinib Effective Long-Term for Advanced RCC

      Tim Cortese
      February 15th 2025
      Article

      Patients with advanced RCC who were treated with nivolumab plus cabozantinib had a median PFS of 16.4 months compared with 8.3 months from sunitinib alone.


      Oncology Nursing News

      A Look Back at 2022 FDA Approvals in Oncology

      Oncology Nursing News
      January 2nd 2023
      Podcast

      In this episode of The Vitals, we recount the oncology drugs that received FDA approvals in 2022.


      Graphic of care providers, patients, and families conversing near large computers and health charts

      Digital Health Tool Helps Patients With Prostate Cancer During Consultations

      Bridget Hoyt
      February 14th 2025
      Article

      MyCareGorithm was met with high approval from patients, companions, and physicians, with all 3 groups reporting they’d recommend the tool to other patients.


      Key Advances in Cancer Survivorship Toxicity Management

      Key Advances in Cancer Survivorship Toxicity Management

      Lindsay Fischer
      July 15th 2022
      Podcast

      In this episode of The Vitals, Lidia Schapira, MD, FASCO, recounts highlights from the 2022 ASCO Symptoms and Survivorship track and underscores key takeaways for practitioners seeking to enhance the delivery of cancer survivorship care.


      Rendering of prostate cancer cells

      Clinical Practice Gaps Persist in Biomarker Testing for mCRPC Management

      Darlene Dobkowski, MA
      February 13th 2025
      Article

      With delays in biomarker testing and treatment for metastatic castration-resistant prostate cancer, continued education is needed to address these gaps.


      Rendering of a bladder and prostate, surrounded by images of cancerous cells

      Talazoparib-Enzalutamide Combo Increases OS in mCRPC

      Jordyn Sava
      February 13th 2025
      Article

      Patients with HRR-deficient metastatic castration-resistant prostate cancer saw a 14-month boost in OS and a 38% lower risk of death with talazoparib plus enzalutamide.

      Related Content

      Blue image of kidneys with renal tubules highlighted in red

      Nivolumab Plus Cabozantinib Effective Long-Term for Advanced RCC

      Tim Cortese
      February 15th 2025
      Article

      Patients with advanced RCC who were treated with nivolumab plus cabozantinib had a median PFS of 16.4 months compared with 8.3 months from sunitinib alone.


      Oncology Nursing News

      A Look Back at 2022 FDA Approvals in Oncology

      Oncology Nursing News
      January 2nd 2023
      Podcast

      In this episode of The Vitals, we recount the oncology drugs that received FDA approvals in 2022.


      Graphic of care providers, patients, and families conversing near large computers and health charts

      Digital Health Tool Helps Patients With Prostate Cancer During Consultations

      Bridget Hoyt
      February 14th 2025
      Article

      MyCareGorithm was met with high approval from patients, companions, and physicians, with all 3 groups reporting they’d recommend the tool to other patients.


      Key Advances in Cancer Survivorship Toxicity Management

      Key Advances in Cancer Survivorship Toxicity Management

      Lindsay Fischer
      July 15th 2022
      Podcast

      In this episode of The Vitals, Lidia Schapira, MD, FASCO, recounts highlights from the 2022 ASCO Symptoms and Survivorship track and underscores key takeaways for practitioners seeking to enhance the delivery of cancer survivorship care.


      Rendering of prostate cancer cells

      Clinical Practice Gaps Persist in Biomarker Testing for mCRPC Management

      Darlene Dobkowski, MA
      February 13th 2025
      Article

      With delays in biomarker testing and treatment for metastatic castration-resistant prostate cancer, continued education is needed to address these gaps.


      Rendering of a bladder and prostate, surrounded by images of cancerous cells

      Talazoparib-Enzalutamide Combo Increases OS in mCRPC

      Jordyn Sava
      February 13th 2025
      Article

      Patients with HRR-deficient metastatic castration-resistant prostate cancer saw a 14-month boost in OS and a 38% lower risk of death with talazoparib plus enzalutamide.

      Latest Conference Coverage

      Cilta-Cel Improves QOL, Extends Treatment Breaks vs SOC in R/R Myeloma

      Acupuncture Use in BC Predicted by Social Determinants of Health

      Variability Found in PROs, Gene Expression During AML Induction Chemo

      Blinatumomab-Linked ICANS Cases Higher Than Previously Reported

      View More Latest Conference Coverage
      About Us
      Editorial Board
      Contact Us
      CancerNetwork.com
      CureToday.com
      OncLive.com
      TargetedOnc.com
      Advertise
      Privacy
      Terms & Conditions
      Do Not Sell My Information
      Contact Info

      2 Commerce Drive
      Cranbury, NJ 08512

      609-716-7777

      © 2025 MJH Life Sciences

      All rights reserved.